Insights
Insights From Our Experts
Articles
Single-Arm Data: Turning Limitations into Strengths with Numbers
Randomized controlled trials (RCTs) are at the top of the evidence pyramid because they are designed to be unbiased. Unfortunately, for many medical devices, these types of studies are lacking. This is either because they are…
Eight Key Strategic Considerations When Launching a Global Indirect Treatment Comparison Program for New Products
Indirect treatment comparisons (ITCs) refer to a comparison of different healthcare interventions using data from separate studies, in contrast to a direct comparison within randomized controlled trials (RCTs). Indirect treatment comparisons are often used because of…
Bringing a CPT Code to Life to Help in the Fight Against Cancer
An interview with Navid Alipour, CEO of CureMatch, and Brian Abraham, Sr. Director, Market Access & Patient Services with EVERSANA On January 1, CureMatch, a leader in precision medicine that has developed a unique analytical platform…
Can Telehealth Accelerate the Uptake of Digital Therapeutics?
Introducing an industry-first, integrated direct-to-patient telehealth solution for digital therapeutics that includes patient engagement, telehealth consultation, prescription issuing and dispensing, and patient support. Fueled by the pandemic, telehealth has moved from an interest to expectation for…
Critical Success Factors for Launching Products with Orphan Drug Designation
The Orphan Drug Act (ODA) was passed in 1983 to financially incentivize pharmaceutical companies to develop drugs for rare diseases or conditions, defined as a disease or condition that affects less than 200,000 people in the…
Filling Evidence Gaps Through Consensus: Revisiting the Delphi Technique
With the launch of any medical device, companies and healthcare providers must be thoughtful about answering the following questions: Who will benefit from this device? What problem does it address? How does this device fit into…
Bending the “Commercialization Curve” in Large Pharma
If the last few years have taught us anything, it’s that it’s more important than ever to embrace change and new ways to bring therapies to patients. This is especially the case when considering commercialization and…
Missed Connection or Meant to Be?
EVERSANA is raising the questions the industry is thinking but is too afraid to ask aloud: Has omnichannel lived up to its promise of the “right message at the right time” to drive meaningful results that…
Account Engagement Excellence: How Advanced Analytics Can Enable Next-Generation Account Segmentation
Account/customer segmentation is a crucial exercise at the beginning of any strategy related to healthcare provider, patient, or payer engagement. Due to the large variety of customers, it is critical to know one’s customers well, from…
Trade & Channel Strategies: Partnership Pavilion Panel
Panel Summary: The challenges of commercialization are abundant. Now more than ever, the right partner and understanding the patient journey are pivotal to commercialization success and ensuring patient access to therapy. During this panel, EVERSANA, EVOKE…